TIDMHIK
RNS Number : 2552J
Hikma Pharmaceuticals Plc
25 April 2022
Hikma Pharmaceuticals PLC
Results of 2022 Annual General Meeting
LONDON, 25 April 2022 Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75)
announces its Annual General Meeting ("AGM"), held at 1 New
Burlington Place, W1S 2HR, London on 25 April 2022 commenced at
1:00 pm. Resolution 15 was withdrawn from the business of the
meeting and all the proposed resolutions were duly passed by
shareholders by way of a poll. Resolutions 1 to 14 were passed as
ordinary resolutions and Resolutions and 16 to 20 were passed as
special resolutions.
The shareholder support for the re-election of the Chair of the
Nomination and Governance Committee (resolution 8) has reduced from
circa 97% in 2021 to 69% today. Following feedback from
shareholders prior to the meeting, the Board understands that this
was due to the level of female representation on the board falling
to 22% as at the end of the AGM following the retirement of Dr.
Pamela Kirby. The Board had envisaged that Dr. Kirby would step
down in 2023 but understands that she wished to move on earlier
than anticipated. The Board is in the process of reviewing
candidates to raise the level of female representation to meet or
exceed its target of 33%. The Board has noted the recent
announcement from the FCA regarding gender diversity and is taking
steps to ensure that these requirements are met within the
established timeframe. The Board will provide an update on progress
within six months of the AGM and in the next annual report.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the FCA's Electronic Submission
System and will be available from the National Storage
Mechanism.
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 23 February 2022) is set out below. The number of
Ordinary Shares in issue on 25 April 2022 was 239,588,352. There
were 12,833,233 Ordinary Shares held in treasury, which are not
counted in the voting capital of the Company which, therefore, was
226,755,119.
Resolution Votes For % Votes Against % Total Cast Withheld
1. To receive the
2021 report and
accounts 171,860,023 100.00 2 0.00 171,860,025 1,357,656
------------ ------- -------------- ------ ------------ ----------
2. To approve a
final dividend of
36 cents per share 173,183,661 99.98 37,842 0.02 173,221,503 1,083
------------ ------- -------------- ------ ------------ ----------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 172,098,319 99.35 1,121,992 0.65 173,220,311 2,275
------------ ------- -------------- ------ ------------ ----------
4. To authorise
the Audit Committee
to determine the
auditors' remuneration 173,218,565 100.00 2,828 0.00 173,221,393 1,193
------------ ------- -------------- ------ ------------ ----------
5. To re-elect
Said Darwazah as
a director 161,582,905 94.37 9,648,531 5.63 171,231,436 1,991,150
------------ ------- -------------- ------ ------------ ----------
6. To re-elect
Siggi Olafsson as
a director 170,660,361 98.52 2,559,312 1.48 173,219,673 2,913
------------ ------- -------------- ------ ------------ ----------
7. To re-elect
Mazen Darwazah as
a director 149,941,788 86.59 23,211,478 13.41 173,153,266 69,320
------------ ------- -------------- ------ ------------ ----------
8. To re-elect
Patrick Butler as
a director 118,035,768 69.01 52,999,954 30.99 171,035,722 2,186,864
------------ ------- -------------- ------ ------------ ----------
9. To re-elect
Ali Al-Husry as
a director 169,733,613 98.03 3,418,717 1.97 173,152,330 70,256
------------ ------- -------------- ------ ------------ ----------
10. To re-elect
John Castellani
as a director 169,693,733 98.09 3,307,545 1.91 173,001,278 216,403
------------ ------- -------------- ------ ------------ ----------
11 . To re-elect
Nina Henderson as
a director 153,383,051 88.55 19,832,207 11.45 173,215,258 2,423
------------ ------- -------------- ------ ------------ ----------
12 . To re-elect
Cynthia Flowers
as a director 156,612,636 90.98 15,518,984 9.02 172,131,620 1,086,061
------------ ------- -------------- ------ ------------ ----------
13 . To re-elect
Douglas Hurt as
a director 153,843,021 88.82 19,370,952 11.18 173,213,973 3,708
------------ ------- -------------- ------ ------------ ----------
14. To approve
the remuneration
report for the year
ended 31 December
2021 157,785,532 91.09 15,426,369 8.91 173,211,901 5,780
------------ ------- -------------- ------ ------------ ----------
15. Withdrawn - - - - - -
------------ ------- -------------- ------ ------------ ----------
16. Authority to
allot shares 164,319,344 95.46 7,812,300 4.54 172,131,644 1,086,037
------------ ------- -------------- ------ ------------ ----------
17 . To dis-apply
pre-emption rights
for general purposes 172,966,280 99.86 248,712 0.14 173,214,992 2,689
------------ ------- -------------- ------ ------------ ----------
18. To dis-apply
pre-emption rights
for an acquisition
or other capital
investment 171,406,211 98.96 1,809,187 1.04 173,215,398 2,283
------------ ------- -------------- ------ ------------ ----------
19. To authorise
the Company to purchase
its own shares 171,959,574 99.36 1,107,248 0.64 173,066,822 155,764
------------ ------- -------------- ------ ------------ ----------
20. To authorise
the Company to hold
general meetings
on no less than
14 clear days' notice 152,971,808 88.31 20,249,569 11.69 173,221,377 1,209
------------ ------- -------------- ------ ------------ ----------
Declaration of final dividend
The dividend of 36 cents per share will be paid on 28 April 2022
to shareholders on the register on 18 March 2022. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $ 1.3021 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa $1 to
0.709JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEUFLIEESEDL
(END) Dow Jones Newswires
April 25, 2022 10:42 ET (14:42 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
